New Lung Cancer Drug Shrinks Tumors 95% in Study

Researchers at Stony Brook Cancer Center developed a new drug that shrank lung cancer tumors by over 95% in laboratory tests and could extend survival by years.

The treatment tackles the biggest problem in cancer care: drug resistance.